Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex

Epilepsia

Volumn 57, Issue 10, 2016, Pages 1617-1624

  Hess, Evan J ^a   Moody, Kirsten A ^a   Geffrey, Alexandra L ^a   Pollack, Sarah F ^a   Skirvin, Lauren A ^a   Bruno, Patricia L ^a   Paolini, Jan L ^a   Thiele, Elizabeth A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cannabidiol; Efficacy; Seizures; Tolerability; Tuberous sclerosis complex

Indexed keywords

CANNABIDIOL; CLOBAZAM; LACOSAMIDE; LAMOTRIGINE; LEVETIRACETAM; NORCLOBAZAM; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; AGITATION; APPETITE DISORDER; ARTICLE; ATAXIA; BEHAVIOR DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPASSIONATE USE; CONFUSION; CONTROLLED STUDY; DIARRHEA; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESISTANT EPILEPSY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HOSPITALIZATION; HUMAN; IRRITABILITY; KETOGENIC DIET; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SELF STIMULATION; SLEEP DISORDER; TUBEROUS SCLEROSIS; VAGUS NERVE STIMULATION; VOMITING; YOUNG ADULT;

EID: 84990219834     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13499     Document Type: Article

References (23)

1. Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol 2015;14:733–745.
2. Henske EP, Jozwiak S, Kingswood JC, et al. Tuberous sclerosis complex. Nat Rev Dis Primers 2016;2:16035.
3. Chu-shore CJ, Major P, Camposano S, et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010;51:1236–1241.
4. Cilio MR, Thiele EA, Devinsky O. The case for assessing cannabidiol in epilepsy. Epilepsia 2014;55:787–790.
5. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55:791–802.
6. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2015;15:270–278.
7. Francis FM. Cannabinoids for pediatric epilepsy? Up in smoke or real science? Transl Pediatr 2015;4:271–282.
8. Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N Engl J Med 2015;373:1048–1058.
9. Welty TE, Luebke A, Gidal BE. Cannabidiol: promise and pitfalls. Epilepsy Curr 2014;4:250–252.
10. Chesher GB, Jackson DM. Anticonvulsant effects of cannabinoids in mice: drug interactions within cannabinoids and cannabinoid interactions with phenytoin. Psychopharmacologia 1974;37:255–264.
11. Chesher GB, Jackson DM, Malor RM. Interaction of delta9-tetrahydrocannabinol and cannabidiol with phenobarbitone in protecting mice from electrically induced convulsions. J Pharm Pharmacol 1975;27:608–609.
12. Consroe PF, Wolkin AL. Anticonvulsant interaction of cannabidiol and ethosuximide in rats. J Pharm Pharmacol 1977;29:500–501.
13. Consroe P, Benedito MA, Leite JR, et al. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 1982;83:293–298.
14. Izquierdo I, Tannhauser M. Letter: The effect of cannabidiol on maximal electroshock seizures in rats. J Pharm Pharmacol 1973;25:916–917.
15. Jones NA, Hill AJ, Smith I, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 2010;332:569–577.
16. Jones NA, Glyn SE, Akiyama S, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 2012;21:344–352.
17. Turkanis SA, Smiley KA, Borys HK, et al. An electrophysiological analysis of the anticonvulsant action of cannabidiol on limbic seizures in conscious rats. Epilepsia 1979;20:351–363.
18. Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980;21:175–185.
19. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2012;6:CD009270.
20. Geffrey AL, Pollack SF, Bruno PL, et al. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 2015;56:1246–1251.
21. GW pharmaceuticals announces positive phase 3 pivotal study results for epidiolex (cannabidiol). Cambridge, UK: GW Pharmaceuticals; 2016. Available at:http://www.gwpharm.com/GW%20Pharmaceuticals%20Announces%20Positive%20Phase%203%20Pivotal%20Study%20Results%20for%20Epidiolex%20cannabidiol.aspx. Accessed April 3, 2016.
22. Abou-Khalil BW. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat 2008;4:507–523.
23. Glauser TA, Ayala R, Elterman RD, et al. Double-blind placebo controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006;66:1654–1660.